Pursuing
Class II FDA clearance
Next Milestone
Clinical Study 2027
WE MAKE PAIN
measurable.
To bring Pain Care to the standard we've already set for diabetes, heart disease, and every other dynamic condition.
“Medicine asks you to make perfect decisions with imperfect information.”* We strive to make that information more perfect.
*Siddhartha Mukherjee, The Laws of Medicine
The scope of the problem
Americans report chronic pain
Are misdiagnosed for years.
The annual cost for the United States.
Because
The gold standard for pain care is still “Pick a number between 0 - 10.”
Despite the complexity of pain
01
Nociceptive pain
Tissue Damage
Sprains, fractures, arthritis, post-surgical pain.
02
Neuropathic pain
Nerve Damage
Spinal cord injury pain, diabetic neuropathy, post-herpetic neuralgia, sciatica.
03
Nociplastic pain
Altered Pain Processing
Fibromyalgia, irritable bowel syndrome, many chronic low back pain cases.
What that cost us
That subjectivity has driven years of misdiagnosis and noisy clinical trials.
Drug
Neuromodulation Devices
Pain care reimagined
OBJECTIVE PAIN INTELLIGENCE FOR MORE ACCURATE TREATMENT + OPIOID TITRATION
Physiology
Clinical Wearable
Continuous physiological monitoring
Experience
Patient app
Lived Experience of Pain
Diagnostics
Clinical Platform
Clinical interpretation
Intelligence
AI
A structured, longitudinal pain signal for clinical decision-making.
THE STORY OF PAIN
1921
Visual Analog Scale
Hayes and Patterson introduced the Visual Analog Scale, a 100mm line from no pain to worst pain imaginable that patients mark to self-report intensity.
1983
Wong-Baker FACES Scale
Donna Wong and Connie Baker developed the FACES Pain Rating Scale for pediatric patients, later adapted to a 0-2-4-6-8-10 numeric scale for easier charting.
2013
fMRI Neurologic Pain Signature
fMRI-based neurologic signature of physical pain in the New England Journal of Medicine
2016
fMRI Distinguishes Real Drug Effects
fMRI with capsaicin-induced sensitization to show gabapentin, but not ibuprofen or placebo, altered pain-related brain activity
2020
Protein and Proteomic Biomarker Panels
Researchers increasingly studied CRP, IL-6, and TNF-alpha as the most consistent inflammatory correlates of chronic musculoskeletal pain, alongside multi-protein and microRNA panels.
2025
Large-Scale Blood Biomarker Prediction study
The synthesis of evidence from systematic reviews and meta-analyses concludes that no single biomarker for chronic pain has achieved sufficient prospective validation for routine clinical use
2026
Objective Pain Intelligence
TEAM
Built by engineers, clinicians, and scientists from Weill Cornell Medicine, Harvard, Pratt, Amazon, and Medtronic.
Sushir Kadidal
CEO. Engineering. Industrail Design.
Harry Sin, MBA
COO. Biomedical Engineering.
Dr. Bobak Mosadegh, PhD
CSO. Clinical Research.
ADVISORS
Dr. Rohan Jotwani, MD, MBA
Interventional Pain
Dr. JoAnn Difede, PhD
Clinical Psychology and Clinical Trials
Shepard Bentley
Regulatory affairs
NOCI
MAKING PAIN MEASURABLE
Noci Corporation. All Rights Reserved.
Pursuing
Class II FDA clearance
Next Milestone
Clinical Study 2027
WE MAKE PAIN
measurable.
To bring Pain Care to the standard we've already set for diabetes, heart disease, and every other dynamic condition.
“Medicine asks you to make perfect decisions with imperfect information.”* We strive to make that information more perfect.
*Siddhartha Mukherjee, The Laws of Medicine
The scope of the problem
Americans report chronic pain
Are misdiagnosed for years.
The annual cost for the United States.
Because
The gold standard for pain care is still “Pick a number between 0 - 10.”
Despite the complexity of pain
01
Nociceptive pain
Tissue Damage
Sprains, fractures, arthritis, post-surgical pain.
02
Neuropathic pain
Nerve Damage
Spinal cord injury pain, diabetic neuropathy, post-herpetic neuralgia, sciatica.
03
Nociplastic pain
Altered Pain Processing
Fibromyalgia, irritable bowel syndrome, many chronic low back pain cases.
What that cost us
That subjectivity has driven years of misdiagnosis and noisy clinical trials.
Drug
Neuromodulation Devices
Pain care reimagined
OBJECTIVE PAIN INTELLIGENCE FOR MORE ACCURATE TREATMENT + OPIOID TITRATION
THE STORY OF PAIN
TEAM
Built by engineers, clinicians, and scientists from Weill Cornell Medicine, Harvard, Pratt, Amazon, and Medtronic.
Sushir Kadidal
CEO. Engineering. Industrail Design.
Harry Sin, MBA
COO. Biomedical Engineering.
Dr. Bobak Mosadegh, PhD
CSO. Clinical Research.
ADVISORS
Dr. Rohan Jotwani, MD, MBA
Interventional Pain
Dr. JoAnn Difede, PhD
Clinical Psychology and Clinical Trials
Shepard Bentley
Regulatory affairs
NOCI
MAKING PAIN MEASURABLE
Noci Corporation. All Rights Reserved.
Pursuing
Class II FDA clearance
Next Milestone
Clinical Study 2027
WE MAKE PAIN
measurable.
To bring Pain Care to the standard we've already set for diabetes, heart disease, and every other dynamic condition.
“Medicine asks you to make perfect decisions with imperfect information.”* We strive to make that information more perfect.
*Siddhartha Mukherjee, The Laws of Medicine
The scope of the problem
Americans report chronic pain
Are misdiagnosed for years.
The annual cost for the United States.
Because
The gold standard for pain care is still “Pick a number between 0 - 10.”
Despite the complexity of pain
01
Nociceptive pain
Tissue Damage
Sprains, fractures, arthritis, post-surgical pain.
02
Neuropathic pain
Nerve Damage
Spinal cord injury pain, diabetic neuropathy, post-herpetic neuralgia, sciatica.
03
Nociplastic pain
Altered Pain Processing
Fibromyalgia, irritable bowel syndrome, many chronic low back pain cases.
What that cost us
That subjectivity has driven years of misdiagnosis and noisy clinical trials.
Drug
Neuromodulation Devices
Pain care reimagined
OBJECTIVE PAIN INTELLIGENCE FOR MORE ACCURATE TREATMENT + OPIOID TITRATION
Physiology
Clinical Wearable
Continuous physiological monitoring
Experience
Patient app
Lived Experience of Pain
Diagnostics
Clinical Platform
Clinical interpretation
Intelligence
AI
A structured, longitudinal pain signal for clinical decision-making.
THE STORY OF PAIN
TEAM
Built by engineers, clinicians, and scientists from Weill Cornell Medicine, Harvard, Pratt, Amazon, and Medtronic.
Sushir Kadidal
CEO. Engineering. Industrial Design.
Harry Sin, MBA
COO. Biomedical Engineering.
Dr. Bobak Mosadegh, PhD
CSO. Clinical Research.
ADVISORS
Dr. Rohan Jotwani, MD, MBA
Interventional Pain
Dr. JoAnn Difede, PhD
Clinical Psychology and Clinical Trials
Shepard Bentley
Regulatory affairs
NOCI
MAKING PAIN MEASURABLE
Noci Corporation. All Rights Reserved.